Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
about
Advances in antibiotic therapy in the critically illPseudomonas aeruginosa ventilator-associated pneumonia managementOptimizing antimicrobial therapy in critically ill patientsYear in review 2013: Critical Care--respiratory infectionsTherapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?Antibiotic stewardship in the intensive care unit.Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patientsNew β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conferenceIndividualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections.High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies.Treatment of bloodstream infections in ICUsStrategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious DiseasesPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceOutcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study.Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?Bloodstream infections in the Intensive Care Unit.Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute InfectionsImpact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies.Treatment option for sepsis in children in the era of antibiotic resistance.Good practice recommendations for paediatric outpatient parenteral antibiotic therapy (p-OPAT) in the UK: a consensus statement.Interethnic differences in pharmacokinetics of antibacterials.Ventilator-associated pneumonia: present understanding and ongoing debates.Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.
P2860
Q26749328-85FB5680-07C4-4B51-838F-0703BF41899EQ26768365-78600BAF-0BC0-4D00-9033-E7B08BE7178DQ26999905-23F57796-0362-409C-8BA1-ED75E26DB18DQ27003346-925C5924-A0C7-4209-8A9D-90B966BD199AQ28080607-7F0D069E-FDB9-4EA7-B84F-C3E1FA4A9DCEQ30408712-770A8B9A-FFE5-4C10-97B3-3B5B0ED67B54Q33552161-16158B9A-6A5F-4F3C-B3A8-8EDEA9F86238Q33622976-667B1572-0BF7-41CA-B3AA-46BF6FE1D355Q33640559-E4A7F741-9121-4388-98C0-E2CEFD27E69BQ33798203-FBCD39A9-25EE-43B5-B45B-4437301A9E77Q33892834-5E823B7A-F1A5-4DE9-969C-15C63DAD2187Q34057385-C090A189-9520-4170-B879-697F920F924CQ34274190-66FB4547-253A-4E83-B3A6-BB6B6DBB693EQ34418911-F9353EF5-E348-4B26-AE0C-5CE154D2ED0CQ34896896-9AC5A5D6-B670-428E-8572-1B696C91EF69Q35986250-82650154-B312-4E1E-83E2-95FF25E1160CQ36083619-24A7DF11-E963-4F1D-9F5C-6A440A3E44FAQ36089167-3A29CEA5-E80E-4F1D-806E-E75A167701A4Q36161206-8F299AEF-903D-4196-90E1-FEDAE170E34EQ36517624-080F7EFC-0996-421D-83DA-560C1E76B042Q36913336-918801F3-228B-4C76-A2AC-0D3B2917CA45Q36969880-EF60E01E-8B4F-4463-A9F2-72CFF8352CB8Q36970989-F1105EF6-5DBB-472B-881C-F89B9DE66850Q37146405-2B9A840C-B2ED-4D16-B213-A9AF3F7FCB40Q37306664-5E10A41F-94BD-4FBC-AB49-6C50E57F4D14Q37335725-31E3A6D3-2850-4207-A38E-6859139BF8C8Q37563029-7AD113E1-3315-489E-9885-45789FFD1D84Q37642084-2DC0045D-BF22-49E8-8296-05731F8F46B4Q37713040-8491C450-22DB-4DE9-B898-A92E8181605CQ38110142-CD88761E-5EC4-47E9-9373-563068EEB45EQ38117578-92561803-3CA3-4B5D-A61C-A05879ACED6CQ38138835-39EA0BCF-3725-4D2D-84BA-260F99B1FE23Q38167345-49E39284-FA51-402D-84C4-0824FCB2136FQ38232197-CA21018A-4711-4349-8226-42415DBF3E29Q38246118-DC6415D6-C30C-42C4-9B90-E068EB4C507AQ38261504-5B412CE6-7BB0-4F82-845C-0A29026350EFQ38266806-9B66828A-DEE4-4D03-841A-0F6E302519BFQ38271775-29519FDC-0AAB-435F-B9E2-62C410B2F522Q38644824-8F1935CF-1F98-4A08-BAD5-64A534F697B7Q38672016-68DB252D-56D0-47B1-8B6C-E88EB52DD492
P2860
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Continuous infusion of beta-la ...... , randomized controlled trial.
@en
Continuous infusion of beta-la ...... , randomized controlled trial.
@nl
type
label
Continuous infusion of beta-la ...... , randomized controlled trial.
@en
Continuous infusion of beta-la ...... , randomized controlled trial.
@nl
prefLabel
Continuous infusion of beta-la ...... , randomized controlled trial.
@en
Continuous infusion of beta-la ...... , randomized controlled trial.
@nl
P2093
P50
P356
P1476
Continuous infusion of beta-la ...... , randomized controlled trial.
@en
P2093
Charudatt Shirwadkar
Glenn M Eastwood
John Myburgh
Joshua S Davis
Steven A R Webb
P304
P356
10.1093/CID/CIS856
P407
P577
2012-10-16T00:00:00Z